<DOC>
	<DOCNO>NCT02240680</DOCNO>
	<brief_summary>To investigate efficacy , safety , tolerability linagliptin 5 milligram day compare placebo add-on therapy 24 week stable basal insulin treatment elderly patient , 60 year age old , Type 2 Diabetes Mellitus insufficient glycaemic control.Stable background therapy metformin and/or alpha-glucosidase inhibitor also allow . In addition , trial ass linagliptin reduces risk hypoglycaemia add background basal insulin therapy . The treatment duration trial ( 24 week ) enable assessment clinically relevant endpoint decrease glycosylated Haemoglobin , well-accepted measurement chronic glycaemic control .</brief_summary>
	<brief_title>Linagliptin Add Basal Insulin Elderly</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Patients must sign date Informed Consent consistent International Conference Harmonisation Good Clinical Practice guideline local regulation prior evaluation participation trial . Male female patient clinical diagnosis Type 2 Diabetes Mellitus , time Informed Consent , : 60 year age old informed consent Screen Visit , take stable dos basal biosimilar basal insulin [ strictly inclusive : insulin neutral protamine Hagedorn isophane insulin ; Humalog Basal ( suspension insulin lispro protamine ) ; insulin degludec ; insulin detemir ; insulin glargine ] least 4 week prior randomisation ( Visit 3 ) dose adjustment maximum plus minus 20 % baseline allow , may may take metformin immediate release extend release [ patient take metformin , stable dose must maintain least twelve week without dose adjustment prior randomisation ( Visit 3 ) ] , may may take alphaglucosidase inhibitor [ acarbose , miglitol , voglibose ; patient take alphaglucosidase inhibitor , stable dose must maintain least twelve week without dose adjustment prior randomisation ( Visit 3 ) ] . Patients must glycosylated Haemoglobin 7.0 % ( 53 millimoles per mole ) 10.0 % ( 86 millimoles per mole ) first visit ( Screen ) . Patients must Body Mass Index 45 kilogram/meter square less Screen Visit . In investigator 's opinion , patient must reliable , compliant , agree cooperate plan future trial evaluation explain detail inform consent process able perform . Exclusion criterion : Impaired cognitive ability support Saint Louis University Mental Status Examination , additional assessment necessary , verified investigator Screen Visit . Depressed mood support score 10 Patient Health Questionnaire Screen Visit . Type 1 Diabetes Mellitus determine past medical record history . Acute coronary syndrome ( nonST Elevation Myocardial Infarction , ST Elevation Myocardial Infarction , and/or unstable angina pectoris ) , stroke transient ischemic attack within 3 month prior Screen Visit . Indication liver disease determine Screen and/or RunIn Period , define serum level 3 time upper limit normal following : alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase . Bariatric , gastric bypass , gastrointestinal procedure surgery ( include type gastric banding , restriction , and/or LapBand ) objective promote weight loss within past two year Screen Visit . Medical history cancer ( except resect noninvasive basal squamous cell carcinoma ) and/or treatment cancer within last 5 year . Blood dyscrasia disorder cause hemolysis unstable red blood cell ( malaria , babesiosis , haemolytic anaemia ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>